Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313766 | 0.88 | ALDH1A1 (0.46) | ALDH1A1TSHRLMNACES2CES1 | |
| SCHEMBL11797960 | 0.84 | TSHR (0.50) | ALDH1A1TSHRLMNACES2CES1 | |
| SCHEMBL11798021 | 0.84 | TSHR (0.50) | ALDH1A1TSHRLMNACES2CES1 | |
| SCHEMBL11793562 | 0.84 | TSHR (0.50) | ALDH1A1TSHRLMNACES2CES1 | |
| SCHEMBL11577758 | 0.84 | TSHR (0.50) | ALDH1A1TSHRLMNACES2CES1 | |
| SCHEMBL11799548 | 0.84 | TSHR (0.50) | ALDH1A1TSHRLMNACES2CES1 | |
| SCHEMBL6312664 | 0.82 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL23292877 | 0.80 | ALDH1A1 (0.48) | ALDH1A1TSHRLMNACES2CES1 | |
| SCHEMBL14321023 | 0.80 | ALDH1A1 (0.48) | ALDH1A1TSHRLMNACES2CES1 | |
| SCHEMBL6314330 | 0.78 | ALDH1A1 (0.46) | ALDH1A1TSHRLMNACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250946-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | PHARMASSET, INC. | 2005-11-10 | — | — | US | disclosed |
| US-6927291-B2 | Method for the synthesis of 2′,3′-dideoxy-2′,3′-didehydronucleosides | PHARMASSET, LTD. (US) | 2005-08-09 | — | — | US | disclosed |
| CN-1505635-A | Synthesis method of 2 ', 3' -dideoxy-2 ', 3' -didehydronucleoside | — | 2004-06-16 | — | — | CN | disclosed |
| EP-1363927-A2 | METHOD FOR THE SYNTHESIS OF 2',3'-DIDEOXY-2',3'-DIDEHYDRONUCLEOSIDES | Pharmasset Limited (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020198224-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | GILEAD PHARMASSET LLC | 2002-12-26 | — | — | US | disclosed |
| WO-2002070533-A2 | METHOD FOR THE SYNTHESIS OF 2',3'-DIDEOXY-2',3'-DIDEHYDRONUCLEOSIDES | PHARMASSET LTD. (BB) | 2002-09-12 | — | — | WO | disclosed |
| US-3998807-A | ARABINOFURANOSYL CYTOSINES AND METHODS OF MAKING | SYNTEX (U.S.A.) INC. (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198224-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | DUT, DUS2, DERA | ALDH1A1 853/4885TSHR 3167/4885LMNA 696/4885 |
| US-20050250946-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | DUT, DERA, DUS2 | ALDH1A1 837/4885TSHR 3180/4885LMNA 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.